Skip to main content
N

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ASX Professional, scientific and technical activities
Open in API
Filings indexed 465 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
First Site Activated in Nyradas PROTECT-MI Phase IIa Trial 6 pages 383.6KB
Regulatory Filings Classification · 1% confidence The document is a corporate announcement (ASX-style press release) detailing the activation of the first clinical trial site and providing background on the trial design and drug candidate. It is not a financial report (10-K, IR, ER), not an investor slide deck, and does not announce dividends, share issues, or management changes. It reads as a general regulatory announcement that doesn’t fit a more specific category, so it should be classified under Regulatory Filings (RNS).
2026-04-21 English
Quarterly Activities Report and Appendix 4C 9 pages 643.1KB
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Activities Report' combined with an 'Appendix 4C' (a standard ASX regulatory form for quarterly cash flow reporting). It provides substantive financial data, including cash flow statements, operating expenses, and business activity updates for the quarter ending 31 March 2026. As it contains comprehensive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q3 2026
2026-04-14 English
Presentation - ASX SMIDCaps Conference 12 pages 1.3MB
Regulatory Filings
2026-03-19 English
Nyrada PROTECT-MI Phase IIa Trial To Commence 6 pages 386.1KB
Regulatory Filings
2026-03-18 English
Change of Director's Interest Notice - JM 3 pages 7.0KB
Regulatory Filings
2026-03-08 English
Notification regarding unquoted securities - NYR 12 pages 41.7KB
Regulatory Filings
2026-02-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.